Literature DB >> 16981244

Evolution of VHL tumourigenesis in nerve root tissue.

A O Vortmeyer1, M G B Tran, W Zeng, S Gläsker, C Riley, M Tsokos, B Ikejiri, M J Merrill, M Raffeld, Z Zhuang, R R Lonser, P H Maxwell, E H Oldfield.   

Abstract

Haemangioblastomas are the key central nervous system manifestation of von Hippel-Lindau (VHL) disease, which is caused by germline mutation of the VHL gene. We have recently shown that 'tumour-free' spinal cord from patients with VHL disease contains microscopic, poorly differentiated cellular aggregates in nerve root tissue, which we descriptively designated 'mesenchymal tumourlets'. Here we have investigated spinal cord tissue affected by multiple tumours. We show that a small subset of mesenchymal tumourlets extends beyond the nerve root to form proliferative VHL-deficient mesenchyme and frank haemangioblastoma. We thus demonstrate that tumourlets present potential, but true precursor material for haemangioblastoma. We further show that intraradicular tumourlets consist of scattered VHL-deficient cells with activation of HIF-2alpha and HIF-dependent target proteins including CAIX and VEGF, and are associated with an extensive angiogenic response. In contrast, activation of HIF-1alpha was only observed in the later stages of tumour progression. In addition, ultrastructural examination reveals gradual transition from poorly differentiated VHL-deficient cells into vacuolated cells with a 'stromal' cell phenotype. The evolution of frank haemangioblastoma seems to involve multiple steps from a large pool of precursor lesions. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981244     DOI: 10.1002/path.2062

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  VHL-deficient vasculogenesis in hemangioblastoma.

Authors:  Sven Gläsker; Jonathan Smith; Mark Raffeld; Jie Li; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Exp Mol Pathol       Date:  2014-01-04       Impact factor: 3.362

Review 2.  Systemic VHL gene functions and the VHL disease.

Authors:  Hannah L Bader; Tien Hsu
Journal:  FEBS Lett       Date:  2012-04-25       Impact factor: 4.124

Review 3.  Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.

Authors:  Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

4.  Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.

Authors:  Gautam U Mehta; Sharon B Shively; Heng Duong; Maxine G B Tran; Travis J Moncrief; Jonathan H Smith; Jie Li; Nancy A Edwards; Russell R Lonser; Zhengping Zhuang; Marsha J Merrill; Mark Raffeld; Patrick H Maxwell; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

5.  Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.

Authors:  Ian J Frew; Andrea Minola; Strahil Georgiev; Manuela Hitz; Holger Moch; Stéphane Richard; Alexander O Vortmeyer; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

6.  Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease.

Authors:  S B Shively; S Beltaifa; B Gehrs; H Duong; J Smith; N A Edwards; Rr Lonser; M Raffeld; A O Vortmeyer
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

7.  The vestibular aqueduct: site of origin of endolymphatic sac tumors.

Authors:  Russell R Lonser; Martin Baggenstos; H Jeffrey Kim; John A Butman; Alexander O Vortmeyer
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

Review 8.  Von Hippel-Lindau disease.

Authors:  Prashant Chittiboina; Russell R Lonser
Journal:  Handb Clin Neurol       Date:  2015

9.  Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling.

Authors:  Kristen J Champion; Maria Guinea; Vincent Dammai; Tien Hsu
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  Risk of new tumors in von Hippel-Lindau patients depends on age and genotype.

Authors:  Marie Louise Mølgaard Binderup; Esben Budtz-Jørgensen; Marie Luise Bisgaard
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.